BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, Bañares R, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Torres F, Bosch J. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597-608. [PMID: 30910320 DOI: 10.1016/S0140-6736(18)31875-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 27] [Article Influence: 35.0] [Reference Citation Analysis]
Number Citing Articles
1 Shimizu T, Shun A, Thomas G. Portosystemic shunt for portal hypertension after Kasai operation in patients with biliary atresia. Pediatr Surg Int 2021;37:101-7. [PMID: 33201302 DOI: 10.1007/s00383-020-04773-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Aday A, O'Leary JG. Acute on Chronic Liver Failure: Definition and Implications. Clin Liver Dis 2020;24:521-34. [PMID: 32620286 DOI: 10.1016/j.cld.2020.04.004] [Reference Citation Analysis]
3 Garcia Garcia de Paredes A, Manicardi N, Tellez L, Ibañez L, Royo F, Bermejo J, Blanco C, Fondevila C, Fernandez Lanza V, Garcia-Bermejo L, Falcon-Perez JM, Bañares R, Gracia-Sancho J, Albillos A. Molecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature. Hepatol Commun 2021;5:309-22. [PMID: 33553977 DOI: 10.1002/hep4.1642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Gopi S, Mohta S, Saraya A. Outcomes of Portal Pressure-Guided Therapy in Decompensated Cirrhosis With Index Variceal Bleed in Asian Cohort. J Clin Exp Hepatol 2021;11:443-52. [PMID: 34276151 DOI: 10.1016/j.jceh.2020.11.001] [Reference Citation Analysis]
6 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Reference Citation Analysis]
7 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yoon KT, Liu H, Lee SS. β-blockers in advanced cirrhosis: More friend than enemy. Clin Mol Hepatol 2021;27:425-36. [PMID: 33317244 DOI: 10.3350/cmh.2020.0234] [Reference Citation Analysis]
9 Marynissen H, Lodeweyckx T, Bielen D, de Hoon J. Doppler ultrasound to assess the pharmacodynamic effects of splanchnic vasoactive compounds. Br J Clin Pharmacol 2021. [PMID: 34558102 DOI: 10.1111/bcp.15095] [Reference Citation Analysis]
10 Benítez C. Pressure Measurements Under Pressure: Simplifying the Diagnosis of Clinically Significant Portal Hypertension. Dig Dis Sci 2021. [PMID: 34739622 DOI: 10.1007/s10620-021-07283-w] [Reference Citation Analysis]
11 de Mattos ÂZ, Terra C, Farias AQ, Bittencourt PL, Alliance of Brazilian Centers for Cirrhosis Care–the ABC Group. Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies. World J Gastrointest Endosc 2021; 13(12): 628-637 [DOI: 10.4253/wjge.v13.i12.628] [Reference Citation Analysis]
12 Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2021:S1590-8658(21)00778-7. [PMID: 34799282 DOI: 10.1016/j.dld.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu L, Nie Y, Zhang Y, Liu Q, Zhu X. Liver Stiffness Is a Predictor of Rebleeding in Patients With Hepatitis B-Related Cirrhosis: A Real-World Cohort Study. Front Med (Lausanne) 2021;8:690825. [PMID: 34395474 DOI: 10.3389/fmed.2021.690825] [Reference Citation Analysis]
14 Yoon U, Topper J, Goldhammer J. Preoperative Evaluation and Anesthetic Management of Patients With Liver Cirrhosis Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2020:S1053-0770(20)30816-8. [PMID: 32891522 DOI: 10.1053/j.jvca.2020.08.022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Reiberger T. The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis. Hepatol Commun 2021. [PMID: 34904404 DOI: 10.1002/hep4.1855] [Reference Citation Analysis]
16 Li TH, Liu CW, Huang CC, Tsai YL, Huang SF, Yang YY, Tsai CY, Hou MC, Lin HC. Non-Selective Beta-Blockers Decrease Infection, Acute Kidney Injury Episodes, and Ameliorate Sarcopenic Changes in Patients with Cirrhosis: A Propensity-Score Matching Tertiary-Center Cohort Study. J Clin Med 2021;10:2244. [PMID: 34064207 DOI: 10.3390/jcm10112244] [Reference Citation Analysis]
17 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
18 Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol 2021;55:721-9. [PMID: 32991355 DOI: 10.1097/MCG.0000000000001431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, Schwabl P, Stättermayer AF, Pinter M, Eigenbauer E, Quehenberger P, Trauner M, Reiberger T, Mandorfer M. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00726-6. [PMID: 34256145 DOI: 10.1016/j.cgh.2021.07.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. [PMID: 32671331 DOI: 10.1016/j.jhepr.2020.100122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
21 Li TH, Tsai YL, Hsu CF, Liu CW, Huang CC, Yang YY, Tsai HC, Huang SF, Hsieh YC, Liu HM, Lee TY, Hou MC, Tsai CY, Lin HC. Propranolol Is Associated with Lower Risk of Incidence of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Tertiary-Center Study and Indirect Comparison with Meta-Analysis. Gastroenterol Res Pract 2020;2020:1892584. [PMID: 32454812 DOI: 10.1155/2020/1892584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
24 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ito K, Hachisu Y, Shibasaki M, Ezawa K, Iwashita H, Jingu A, Arai H, Horie T, Takise A. Liver Cirrhosis and Hepatocellular Carcinoma Diagnosed from Chylothorax: A Case Report. Clin Pract 2021;11:582-6. [PMID: 34563002 DOI: 10.3390/clinpract11030073] [Reference Citation Analysis]
26 Tosetti G, Primignani M. Response to Sharma and Saraya. Am J Gastroenterol 2021;116:1756-7. [PMID: 33927128 DOI: 10.14309/ajg.0000000000001290] [Reference Citation Analysis]
27 Khan F, Tripathi D. Role of early transjugular intrahepatic portosystemic stent-shunt in acute variceal bleeding: An update of the evidence and future directions. World J Gastroenterol 2021; 27(44): 7612-7624 [PMID: 34908802 DOI: 10.3748/wjg.v27.i44.7612] [Reference Citation Analysis]
28 Dajti E, Alemanni LV, Marasco G, Montagnani M, Azzaroli F. Approaches to the Diagnosis of Portal Hypertension: Non-Invasive or Invasive Tests? Hepat Med 2021;13:25-36. [PMID: 33776492 DOI: 10.2147/HMER.S278077] [Reference Citation Analysis]
29 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
30 Asesio N, Pollo-Flores P, Caliez O, Munteanu M, Ngo A, Ngo Y, Poynard T, Thabut D, Rudler M. Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis. Dig Liver Dis 2021:S1590-8658(21)00773-8. [PMID: 34583904 DOI: 10.1016/j.dld.2021.09.004] [Reference Citation Analysis]
31 Bultas AC, Teshome B, Richter SK, Schafers S, Cooke E, Call WB. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications. Ann Pharmacother 2020;54:583-93. [DOI: 10.1177/1060028019893092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Garcia Garcia de Paredes A, Villanueva C, Blanco C, Genescà J, Manicardi N, Garcia-Pagan JC, Calleja JL, Aracil C, Morillas RM, Poca M, Peñas B, Augustin S, Abraldes JG, Alvarado E, Royo F, Garcia-Bermejo ML, Falcon-Perez JM, Bañares R, Bosch J, Gracia-Sancho J, Albillos A. Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. JHEP Rep 2021;3:100368. [PMID: 34712934 DOI: 10.1016/j.jhepr.2021.100368] [Reference Citation Analysis]
34 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
35 Katarey D, Jalan R. Non-selective beta blockers in cirrhosis: time to extend the indications? Ann Transl Med 2019;7:S355. [PMID: 32016073 DOI: 10.21037/atm.2019.09.56] [Reference Citation Analysis]
36 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Maiwall R, Pasupuleti SSR, Jain P, Sarin SK. Degree of Portal and Systemic Hemodynamic Alterations Predict Recurrent AKI and Chronic Kidney Disease in Patients With Cirrhosis. Hepatol Commun 2021;5:293-308. [PMID: 33553976 DOI: 10.1002/hep4.1607] [Reference Citation Analysis]
38 Li Q, Guo X, Feng J, Xu X, Chawla S, Li H, Qi X, Peltekian KM. Risk Factors for Esophageal Collateral Veins in Cirrhosis with and without Previous Endoscopic Esophageal Variceal Therapy. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-13. [DOI: 10.1155/2022/6666791] [Reference Citation Analysis]
39 Xu X, Xu S, Primignani M, De Stefano V, He Y, Yi F, Guo X, Valla D, Qi X. Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. Adv Ther 2020;37:1452-63. [PMID: 32076942 DOI: 10.1007/s12325-020-01250-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
40 Yeh WS, Yang SC, Liang CM, Li YC, Tai WC, Lee CH, Yang YH, Hsu CN, Tsai TH, Chuah SK, Wu CK. The Role of Non-Selective β-Blockers in Compensated Cirrhotic Patients without Major Complications. Medicina (Kaunas) 2019;56:E14. [PMID: 31905956 DOI: 10.3390/medicina56010014] [Reference Citation Analysis]
41 Mir ZM, Djerboua M, Nanji S, Flemming JA, Groome PA. Predictors of Postoperative Liver Decompensation Events After Resection in Patients with Cirrhosis and Hepatocellular Carcinoma: A Population-Based Study. Ann Surg Oncol 2021. [PMID: 34549362 DOI: 10.1245/s10434-021-10801-9] [Reference Citation Analysis]
42 Cullaro G, Sharma R, Trebicka J, Cárdenas A, Verna EC. Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes. Liver Transpl 2020;26:283-93. [PMID: 31714011 DOI: 10.1002/lt.25678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
43 Burghart L, Halilbasic E, Schwabl P, Simbrunner B, Stättermayer AF, Petrenko O, Scheiner B, Bauer D, Pinter M, Boztug K, Mandorfer M, Trauner M, Reiberger T. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. J Gastroenterol 2021. [PMID: 34893924 DOI: 10.1007/s00535-021-01839-3] [Reference Citation Analysis]
44 Podrug K, Trkulja V, Zelenika M, Bokun T, Madir A, Kanizaj TF, O'Beirne J, Grgurevic I. Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography. Dig Dis Sci 2021. [PMID: 34739624 DOI: 10.1007/s10620-021-07277-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73:441-445. [PMID: 32298769 DOI: 10.1016/j.jhep.2020.04.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 35.0] [Reference Citation Analysis]
46 Liu Y, Tang T, Örmeci N, Huang Y, Wang J, Li X, Li Z, An W, Liu D, Zhang C, Liu C, Liu J, Liu C, Wang G, Mosconi C, Cappelli A, Bruno A, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Li L, Zhang H, Kang N, Xu D, He R, Wang Y, Bu Y, Gu Y, Ju S, Golfieri R, Qi X. Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. J Clin Transl Hepatol 2021;9:818-27. [PMID: 34966645 DOI: 10.14218/JCTH.2021.00177] [Reference Citation Analysis]
47 Calès P, Bertrais S, Boursier J, Fouchard I, Oberti F; SNIFF 16 group. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. Liver Int 2021;41:168-79. [PMID: 32979020 DOI: 10.1111/liv.14674] [Reference Citation Analysis]
48 Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, Kasozi KI, Zirintunda G, Aslam A, Allahyani M, Welburn SC, Batiha GE. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19. Front Immunol 2021;12:749291. [PMID: 34867978 DOI: 10.3389/fimmu.2021.749291] [Reference Citation Analysis]
49 Bosch J. Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies. Clin Liver Dis (Hoboken) 2020;15:S8-S12. [PMID: 32140209 DOI: 10.1002/cld.844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Giri S, Kasturi S. Triple-phase CT scan for disease progression prediction in cirrhosis: A valid repurpose? Eur J Radiol 2022;146:110077. [PMID: 34861531 DOI: 10.1016/j.ejrad.2021.110077] [Reference Citation Analysis]
51 Wang SF, Huang YT, Huang CH, Chang SH, Lin CY. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med 2020;8:1223. [PMID: 33178755 DOI: 10.21037/atm-20-2444] [Reference Citation Analysis]
52 Renzulli M, Dajti E, Ierardi AM, Brandi N, Berzigotti A, Milandri M, Rossini B, Clemente A, Ravaioli F, Marasco G, Azzaroli F, Carrafiello G, Festi D, Colecchia A, Golfieri R. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. Eur J Radiol 2021;:110010. [PMID: 34801322 DOI: 10.1016/j.ejrad.2021.110010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Yang Y, Fu S, Cao B, Hao K, Li Y, Huang J, Shi W, Duan C, Bai X, Tang K, Yang S, He X, Lu L. Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study. Hepatol Int 2021;15:730-40. [PMID: 33977364 DOI: 10.1007/s12072-021-10188-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]